Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Utilizing Salmonella to treat solid malignancies.

Ebelt ND, Manuel ER.

J Surg Oncol. 2017 Jul;116(1):75-82. doi: 10.1002/jso.24644. Epub 2017 Apr 18. Review.

PMID:
28420039
2.

Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer.

D'Alincourt Salazar M, Manuel ER, Tsai W, D'Apuzzo M, Goldstein L, Blazar BR, Diamond DJ.

Oncoimmunology. 2016 Mar 16;5(6):e1160184. doi: 10.1080/2162402X.2016.1160184. eCollection 2016 Jun.

3.

Developing Effective Salmonella-based Approaches to Treat Pancreatic Cancer.

Chen J, Diamond DJ, Manuel ER.

Pancreat Disord Ther. 2016;6(1):1-2. No abstract available.

4.

Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.

Ouyang M, White EE, Ren H, Guo Q, Zhang I, Gao H, Yanyan S, Chen X, Weng Y, Da Fonseca A, Shah S, Manuel ER, Zhang L, Vonderfecht SL, Alizadeh D, Berlin JM, Badie B.

PLoS One. 2016 Feb 1;11(2):e0148139. doi: 10.1371/journal.pone.0148139. eCollection 2016.

5.

Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors.

Manuel ER, Chen J, D'Apuzzo M, Lampa MG, Kaltcheva TI, Thompson CB, Ludwig T, Chung V, Diamond DJ.

Cancer Immunol Res. 2015 Sep;3(9):1096-107. doi: 10.1158/2326-6066.CIR-14-0214. Epub 2015 Jul 1.

6.

Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system.

Xu X, Hegazy WA, Guo L, Gao X, Courtney AN, Kurbanov S, Liu D, Tian G, Manuel ER, Diamond DJ, Hensel M, Metelitsa LS.

Cancer Res. 2014 Nov 1;74(21):6260-70. doi: 10.1158/0008-5472.CAN-14-1169. Epub 2014 Sep 11.

7.

Tumor growth control with IDO-silencing Salmonella--reply.

Manuel ER, Blazar BR, Diamond DJ.

Cancer Res. 2013 Jul 15;73(14):4592-3. doi: 10.1158/0008-5472.CAN-13-1274. Epub 2013 Jul 5. No abstract available.

8.
9.

Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth.

Blache CA, Manuel ER, Kaltcheva TI, Wong AN, Ellenhorn JD, Blazar BR, Diamond DJ.

Cancer Res. 2012 Dec 15;72(24):6447-56. doi: 10.1158/0008-5472.CAN-12-0193. Epub 2012 Oct 22.

10.

Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice.

Fan H, Zhang I, Chen X, Zhang L, Wang H, Da Fonseca A, Manuel ER, Diamond DJ, Raubitschek A, Badie B.

Clin Cancer Res. 2012 Oct 15;18(20):5628-38. doi: 10.1158/1078-0432.CCR-12-1911. Epub 2012 Aug 17.

11.

Survivin the battle against immunosuppression.

Manuel ER, Blache CA, Ellenhorn JD, Diamond DJ.

Oncoimmunology. 2012 Mar 1;1(2):240-241.

12.

Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors.

Manuel ER, Blache CA, Paquette R, Kaltcheva TI, Ishizaki H, Ellenhorn JD, Hensel M, Metelitsa L, Diamond DJ.

Cancer Res. 2011 Jun 15;71(12):4183-91. doi: 10.1158/0008-5472.CAN-10-4676. Epub 2011 Apr 28.

13.

Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.

Ishizaki H, Manuel ER, Song GY, Srivastava T, Sun S, Diamond DJ, Ellenhorn JD.

Cancer Immunol Immunother. 2011 Jan;60(1):99-109. doi: 10.1007/s00262-010-0923-0. Epub 2010 Oct 20.

14.

Vaccination reduces simian-human immunodeficiency virus sequence reversion through enhanced viral control.

Manuel ER, Yeh WW, Balachandran H, Clarke RH, Lifton MA, Letvin NL.

J Virol. 2010 Dec;84(24):12782-9. doi: 10.1128/JVI.01193-10. Epub 2010 Sep 29.

15.

Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression.

Ishizaki H, Song GY, Srivastava T, Carroll KD, Shahabi V, Manuel ER, Diamond DJ, Ellenhorn JD.

J Immunother. 2010 Jul-Aug;33(6):609-17. doi: 10.1097/CJI.0b013e3181e032c6.

16.

Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses.

Manuel ER, Wang Z, Li Z, La Rosa C, Zhou W, Diamond DJ.

Virology. 2010 Aug 1;403(2):155-62. doi: 10.1016/j.virol.2010.04.015. Epub 2010 May 14.

17.

Dominant CD8+ T-lymphocyte responses suppress expansion of vaccine-elicited subdominant T lymphocytes in rhesus monkeys challenged with pathogenic simian-human immunodeficiency virus.

Manuel ER, Yeh WW, Seaman MS, Furr K, Lifton MA, Hulot SL, Autissier P, Letvin NL.

J Virol. 2009 Oct;83(19):10028-35. doi: 10.1128/JVI.01015-09. Epub 2009 Jul 29.

18.

Diverse cross-reactive potential and Vbeta gene usage of an epitope-specific cytotoxic T-lymphocyte population in monkeys immunized with diverse human immunodeficiency virus type 1 Env immunogens.

Hulot SL, Seaman MS, Sen P, Autissier PA, Manuel ER, Letvin NL.

J Virol. 2009 Oct;83(19):9803-12. doi: 10.1128/JVI.00776-09. Epub 2009 Jul 29.

19.

Clonal focusing of epitope-specific CD8+ T lymphocytes in rhesus monkeys following vaccination and simian-human immunodeficiency virus challenge.

Sen P, Charini WA, Subbramanian RA, Manuel ER, Kuroda MJ, Autissier PA, Letvin NL.

J Virol. 2008 Jan;82(2):805-16. Epub 2007 Oct 31.

20.

Contribution of T-cell receptor repertoire breadth to the dominance of epitope-specific CD8+ T-lymphocyte responses.

Manuel ER, Charini WA, Sen P, Peyerl FW, Kuroda MJ, Schmitz JE, Autissier P, Sheeter DA, Torbett BE, Letvin NL.

J Virol. 2006 Dec;80(24):12032-40. Epub 2006 Oct 11.

Supplemental Content

Loading ...
Support Center